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Vitamin B12 is a water soluble vitamin known for its many deficiency symptoms. New studies 
on demographics and serum vitamin B12 levels conflict with past results.  The purpose of this 
study was to evaluate the relationships among weight status, serum vitamin B12 levels, and 
vitamin B12 dietary intake in individuals with Type 2 diabetes and diabetic neuropathy. 
A total of 30 participants were recruited from the University of Kansas Medical Center and the 
University of Utah. In a randomized exercise intervention trial (Activity for Diabetic 
Polyneuropathy: ADAPT Study) height, weight, Body Mass Index, medication, supplement use, 
age, serum vitamin B12 values and  dietary intake via 3 day food records were collected at 
baseline visits. The 3 day food records were entered into a nutrition software program (NDSR) to 
determine sources and amount of vitamin B12 consumed for a 3 day average. Descriptive 
statistics were used to characterize the participants. Differences between metformin vs. non-
metformin users were compared using ANOVA. Regression analysis was used to evaluate the 
relationship between serum vitamin B12 and the following variables: weight, age, vitamin B12 
supplement use and oral B12 consumption. A pairwise correlation matrix linked each 
independent variable in a set point in time.  
The mean total vitamin B12 consumption was 4.3 µg per day. The use of the drug metformin 
was not found to be statistically significantly related to serum B12 levels. No relationships were 
found between serum vitamin B12 and age, BMI, or obesity status. The use of vitamin B12 






These findings are encouraging for those who are at risk for vitamin B12 deficiency. The study 
also does not find a negative correlation between age and serum B12 levels, which could indicate 
that screening for deficiency should start at a younger age. Future studies should look at age and 
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Chapter 1: Introduction 
  According to the Centers for Disease Control and Prevention (CDC), 29 million people 
in the United States have diabetes mellitus (1). The World Health Organization (WHO) has 
estimated that 90% of people with Type 2 diabetes are overweight or obese (2). Of the 27.5 
million with type 2 diabetes, 60-70% will develop peripheral neuropathy (DPN) (3) and 22% are 
found to be vitamin B12 deficient (4).  Signs and symptoms of both DPN and vitamin B12 
deficiency are similar and therefore patients undergoing testing for DPN must first eliminate 
vitamin B12 deficiency as the problem. In addition, patients consuming the diabetes medication, 
metformin, increase their risk of vitamin B12 deficiency by 74% (5) , compared with patients 
taking insulin and other forms of biguanides. Other factors can also attribute to low vitamin B12 
levels, including age, diet, malabsorption and other medication usage (6).  Many studies have 
focused on age and the use of metformin as the source of vitamin B12 deficiency. 
 In 1994, the Frammingham study looked at vitamin B12 deficiency in an elderly 
population (≥65 years) (7). They found 40% of individuals 65 years and older were deficient 
while 17.9% of subjects 22-63 years old were deficient (7). Couderc et al found that 57.6% of his 
participants (≥ 64 years) had food cobalamin malabsorption while 12% had nutritional cobalamin 
deficiency, due to inadequate intake of oral vitamin B12 (8).  Solomon et al concluded that 
serum B12 in individuals >70 years old was significantly lower than individuals 60-69 years old 
(9). In contrast, El-Khateeb in 2014 found that younger adults in Jordan (19-30 years old) had the 
highest rates of vitamin B12 deficiency. The study cites multiple other studies with the same 
conclusion (10).  Yajnik’s cross-sectional study found over 67% of men ages 30-50 in rural India 
were vitamin B12 deficient (11).  Similar inconsistencies can be found in the usage of metformin 




     Metformin is the number one recommended drug for individuals diagnosed with pre-
diabetes and diabetes (12-14).  While most studies conclude that patients taking metformin have 
a 10-30% risk of developing vitamin B12 deficiency, there is not consistency in the timeline (4, 
5, 14). Bell et al stated that it takes 12 to 15 years of inadequate vitamin B12 intake in metformin 
users for serum B12 to reflect depleted stores (12). Bauman et al’s clinical trial, however, found 
a decrease in serum B12 after only 3 months of metformin use (13).  The National Health and 
Examination Survey, 1999-2006 cross sectional study, found that duration of metformin use 
increased the risk of vitamin B12 deficiency, but the increased risk was not statistically 
significant (15). Patients taking the medication for <1 year had a 4.1% risk, while there was a 
8.1% risk in subjects taking metformin for >10 years (15). Pflipsen et al conducted a cross-
sectional study on outpatients with Type 2 diabetes. Their study revealed that metformin 
increased the risk of vitamin B12 deficiency, but dosage was not a factor. They specified chronic 
metformin use increased the risk of deficiency, but did not specify the timeframe the authors 
considered chronic. A clinical trial by Singh et al found vitamin B12 deficiency with metformin 
only after 1 year of use (28.5%), and that individuals taking metformin had a statistically 
significant increase in peripheral neuropathy (48.8%) (5).   
 Metformin use, age and other medications have been studied, but there are still gaps in 
the literature. Few studies have evaluated body weight and its relationship to vitamin B12 
deficiency. Only two studies related vitamin B12 deficiency to obesity (10, 16). A population 
based study found that 30.5% of normal and overweight older adults were vitamin B12 deficient, 
while 34.4% of obese older adults were deficient. A prospective descriptive study showed obese 
children had an average of 130pg/mL lower serum B12 when compared to normal weight 




children had low levels (16). Neither study looked at obesity as an independent variable of 
vitamin B12 deficiency.  
The success of vitamin B12 supplementation regarding deficiency and DPN is 
inconsistent and variable (8).  The National Health and Nutrition Examination Survey 
(NHANES) found no association between a lower risk of vitamin B12 deficiency and 
supplementation in individuals taking metformin. Adults taking up to 6µg of vitamin B12 had a 
14.1% risk of becoming deficient, while people taking >6µg of vitamin B12 had a 1.8% risk of 
developing deficiency (15). The Frammingham Offspring prospective Cohort study of Healthy 
Adults, 26 years of age and older, looked at fortified foods, and animal sources of vitamin B12. 
(17). The study found that people who consumed fortified cereal 4 times a week or more, had a 
14% risk of becoming deficient. People who did not consume fortified cereals had a 23% risk of 
becoming deficient. The study also concluded that fortified foods might be better absorbed than 





Statement of Purpose 
 The purpose of this proposed thesis was to further research the correlations between 
weight status, serum vitamin B12 levels, and vitamin B12 dietary intake in individuals with Type 
2 diabetes and diabetic neuropathy 
 
Research Questions  
a. What is the average daily intake (µg) of vitamin B12 in adults with diabetic 
peripheral neuropathy   
b. Is there a difference in serum vitamin B12 levels between metformin vs non-
metformin users? 
c. Is there a relationship between vitamin B12 consumption and serum B12 levels? 
d. Is there a relationship between Body Mass Index and serum B12 levels? 






Chapter 2: Review of Literature 
Introduction:  
More than 29 million Americans have been diagnosed with diabetes mellitus (DM) (18). 
From this group, 60-70% have some form of diabetic neuropathy (19). Diabetes mellitus is now 
the 7th leading cause of death in the United States. Complications related to DM include 
hypertension, stroke, heart attacks, blindness, kidney disease, amputations, cobalamin deficiency 
and death (1).  
Cobalamin (Vitamin B12) deficiency is found in 20% of people over the age of 65 (6, 
8). Certain factors such as diet, age and medications can increase the risk of developing a 
deficiency (20). The purpose of this Literature Review is to review the relationships between 
weight status, serum B12 levels and vitamin B12 dietary intake in adults with diabetic 
neuropathy.   
 
Diabetic Neuropathy:   
          Types of Diabetes Mellitus 
There are two main types of DM; Type 1 and Type 2 (21). Type 2 Diabetes (T2DM) is 
when a hormone called insulin, produced by the pancreas, does not work properly. The insulin is 
not able to pull glucose from the blood for cells to use as fuel (22).  The pancreas then tries to 
overproduce insulin to rectify the problem. The body becomes insulin resistant, which is when 
insulin no longer works properly, leading to hyperglycemia (23).  Overweight and obesity is seen 
in 60-90% of individuals with T2DM (21). Other risk factors include decreased physical activity 




High blood glucose levels produce many co-morbidities. Consistent hyperglycemia leads 
to plaque formation in the arteries. This narrows the vessels and can lead to a stroke or heart 
attack. Kidney damage occurs when the kidneys are required to filter out the extra glucose in the 
blood (23). After time, the kidneys fatigue, leading to failure, potentially requiring 
hemodialysis.    
Diabetic neuropathy is the damage of blood vessels that carry oxygen to the nerves of 
organs, the gastrointestinal tract, extremities and the cardiovascular system (19). Neuropathy is 
found in 60-70% of individuals with T2DM (19).  Chronic high blood glucose causes ischemia, 
the narrowing of the vessels, preventing oxygen and nutrients to travel throughout the body (23). 
Loss of sensation to extremities often leads to injury. When a patient with diabetic neuropathy 
has a wound, blood, nutrients, and oxygen are not able to heal the foot or hands effectively. The 
wound, left untreated, can lead to a diabetic foot ulcer. Eighty-four percent of diabetic foot ulcers 
lead to lower-leg amputations (24).   
There are two main forms of diabetic neuropathy, chronic sensorimotor and autonomic 
neuropathy (2-4, 10). Chronic sensorimotor diabetic peripheral neuropathy is found in about 50% 
of patients with neuropathy (25).  Occurring in the lower limbs, hands and feet; symptoms 
include, warm or cold feet, burning pain, stabbing feelings, tingling sensation, numbing, or deep 
aching pain in the localized area (19, 25).  Autonomic neuropathy (AN) is related to the 
sympathetic and parasympathetic nervous systems. Autonomic neuropathy can affect the nerves 
related to the gastrointestinal tract, cardiovascular system, lungs and eyes (19). The main side 
effect of AN in the gastrointestinal tract is gastroparesis. In this condition the stomach delays 
gastric emptying, which can cause constipation, abdominal pain, and heart burn. Other side 




Medications for Type 2 Diabetes:  
The largest non-insulin medication used for diabetes and pre-diabetes is metformin. It is 
prescribed to over 120 million people in the world, around 1.6% of the population (26). 
Metformin acts as an anti-hyperglycemic agent, preventing high blood glucose levels. The 
medication decreases hepatic glucose production by preventing the liver from producing glucose 
from non-carbohydrate sources. This lowers blood glucose without a risk of hypoglycemia or 
weight gain (26). Side effects of the drug are lactic acidosis, abdominal pain, diarrhea and 
vitamin B12 deficiency (27). The use of metformin lowers vitamin B12 levels by 22% compared 
to individuals with diabetes who were not taking metformin (5).    
 
Vitamin B12  
Vitamin B12, also known as Cobalamin, is a water-soluble vitamin, a cofactor for two 
main enzyme reactions, and a feature in myelin production (6). The first enzyme reaction vitamin 
B12 is involved in is the conversion of methylmalonyl CoA to succinyl CoA. Succinyl CoA is an 
important intermediate of the Citric Acid Cycle, which produces ATP.  The second vitamin B12 
enzyme reaction is the conversion of homocysteine to methionine. Vitamin B12 binds to 
methionine synthase and the following process creates methylcobalamin and 5-methyl 
tetrahydrofolate (THF). Inadequate vitamin B12 can lead to higher serum homocysteine and 
THF levels. THF is important for many coenzymes, while high levels of serum homocysteine 
can lead to cardiovascular problems. Once methionine is created, it is then converted to S-
adenosylmethionine (SAMe) which is a methyl donor. SAMe is needed for the protein myelin, 




 The term vitamin B12 and cobalamin are interchangeable. The term cyanocobalamin 
refers to the synthetic form of vitamin B12 that is taken in supplement form.  Cyanocobalamin 
must first be converted to an active form before being absorbed (23).   
Absorption:   
Cobalamin absorption starts in the mouth. Saliva, along with food containing vitamin 
B12 travel to the stomach. The stomach releases hydrochloric acid (HCl), pepsinogen and 
intrinsic factor. Hydrochloric acid then activates pepsinogen to pepsin, a main digestive enzyme 
(23). An acidic environment is important to activate the stomach enzymes. Pepsin and HCl 
separate vitamin B12 from its food source. The free vitamin B12 then binds with transcobalamin 
1 (TCI) from saliva in the stomach. The TCI-Vitamin B12 complex travels to the duodenum 
where vitamin B12 is separated from TCI and attaches to intrinsic factor, which has traveled 
from the stomach. The vitamin B12 intrinsic factor complex travels to the ileum where intrinsic 
factor receptors allow vitamin B12 absorption into the plasma. The intrinsic factor receptors that 
facilitate vitamin B12 into the blood are calcium dependent (13). Calcium supplementation used 
to prevent vitamin B12 deficiency will be discussed in further detail. Once across the ileum 
surface membrane, vitamin B12 attaches to either TCI or TCII where it is released into the portal 
vein for transport to peripheral tissue (23).  
 Function:    
Vitamin B12 is important for DNA, RNA and red blood cell production. Along with 
being required for two enzymatic reactions, it also plays an important role in lipid synthesis, 
which produces the myelin sheath. The myelin sheath wraps around nerves and protects the axon 
and the nerves from being exposed (28). The conversion of homocysteine back to methionine 




homocysteine (23). Malabsorption or deficiency of vitamin B12 can lead to megaloblastic 
anemia, neuropathy, folate deficiency and cardiovascular disease due to chronic high serum 
homocysteine levels (29).   
Vitamin B12 deficiency:  
Vitamin B12 deficiency is most common in the elderly, vegans, individuals who have 
had any gastrointestinal surgeries and people taking certain medications: proton pump inhibitors 
(PPI) and metformin. Vitamin B12 deficiency affects >20% of people over the age of 65 (6). 
This deficiency is frequently undiagnosed because of non-distinguishable signs and symptoms. 
The two main causes of vitamin B12 deficiency in the elderly are malabsorption and pernicious 
anemia (6). Gastric atrophy, the degeneration or wasting away of cells, occurs in 40% of people 
over the age of 80 (1). This atrophy prevents free vitamin B12 from binding to intrinsic factor 
where it is then absorbed into the blood stream. (8). Bacterial overgrowth, seen with antibiotic 
use, can cause inflammation of the small intestine, which can prevent vitamin B12 absorption 
(1). 
Pernicious anemia is the second main cause of vitamin B12 deficiency. Twenty to forty 
percent of elderly have vitamin B12 deficiency due to pernicious anemia (6). This autoimmune 
disease destroys the cells in the stomach that produce intrinsic factor. In addition to pernicious 
anemia, those taking proton pump inhibitors are also at risk of vitamin B12 deficiency. Proton 
pump inhibitors, decrease the acidity of the stomach, thus reducing intrinsic factor needed for 
absorption. The consumption of alcohol for more than 2 weeks consistently is also seen to 






Signs and symptoms   
Signs and symptoms of vitamin B12 deficiency can include symptoms of megaloblastic 
anemia, fatigue, weakness, abdominal pain and gastroparesis, along with neurological conditions 
such as memory loss, mood changes and neuropathy of the hands and feet (1).  Excessive serum 
homocysteine has been linked to increased  risk of coronary heart disease and stroke (30). 
Homocysteine can decrease vasomotor function of the endothelia and can increase the oxidative 
degradation of lipids (30). 
Vitamin B12 food sources:  
Vitamin B12 is largely found in meats, fish, shellfish, and dairy products (1). The current 
RDA for vitamin B12 ages 12+ is 2.4 µg, while there is no RDA for the elderly (2). The 
NHANES 1999-2000 concluded that the average daily consumption of vitamin B12 in the 
United States was 3.4 µg (30). The US Department of Agriculture (USDA) has compiled a 
database of food sources with their concentrations of vitamin B12 (e.g. fortified breakfast cereals 
contain 6 µg per serving, a cheeseburger with two patties contains 2.1 µg, and 8 ounces of yogurt 
contains 1.1µg (1). Other sources of vitamin B12 include supplementation.  
Laboratory status:  
 The laboratory status of serum cobalamin is the main indicator of vitamin B12 
deficiency. While the precise laboratory value for deficiency may vary slightly between 
laboratories, most major studies use ~150 pmol/L and under, as their diagnostic criteria (31). The 
serum B12 measures cobalamin bound to TCI and TCII. TCI is the only B12 bound protein used 
for metabolic demands (31). Only evaluating TCI when determining appropriate serum B12 
levels could give false high values. Calculating serum B12 levels must be evaluated on an 




deficiency. Excess serum homocysteine of >20 µmol/L, indicates homocysteine is not being 
converted back to methionine via vitamin B12 enzymes. Holotranscobalamin is the active form 
of cobalamin taken into the cells. A level of <35 pmol/L indicates a deficiency of the active form 
of vitamin B12.     
 
Metformin and vitamin B12 deficiency:  
The majority of recent studies conducted on vitamin B12 deficiency are related to the use 
of the medication metformin. Three were cross-sectional studies of individuals with diabetes 
taking versus not taking metformin (4, 5, 15). All studies were under 12 months in length, and 
measured deficiency as serum B12 <100 pg/mL or <150 pg/mL. One study by Pflipsen et al, in 
the United States, found 22% of their study population to be vitamin B12 deficient, and patients 
taking metformin had a higher statistical risk of developing vitamin B12 deficiency (4). They did 
not find a statistical significance between the dosage of metformin and vitamin B12 deficiency. 
The second study, by Singh et al in India, found that 28.5% of their patients taking metformin 
were vitamin B12 deficient; while only 4.7% not taking metformin were deficient (5). NHANES 
1999-2006 discovered 5.8% of their population with diabetes taking metformin were vitamin 
B12 deficient, while 3.3% of those not taking metformin were deficient (15).  In conclusion, the 
studies showed metformin was associated with lower serum B12 levels.   
Two clinical trials looked at the use of metformin in participants with diabetes compared 
to a placebo (13, 14). Bauman et al completed a 6-month study with participants consuming 850 
mg of metformin or a placebo pill twice a day. They found a statistically significant difference in 
serum B12 levels between the metformin and placebo groups after 3 months The metformin 




(13).  Jager et al conducted a 4.3 yearlong study where participants took 850 mg metformin or a 
placebo 3 times a day.  The long-term study found a 19% decrease in vitamin B12 levels 
compared to the placebo group. The metformin group also had a 7% higher risk of developing 
vitamin B12 deficiency (13). Overall, both studies support the theory metformin increases the 
risk vitamin B12 deficiency.  
 
Vitamin B12 deficiency not related to metformin  
Although the use of metformin is known to cause lower levels of vitamin B12, other 
factors such as age, other medication use and diet can also lower vitamin B12 levels. Seven 
studies found that the risk of deficiency increases with age (6, 8, 14, 15, 20, 32-34).  Cutoff age 
range varied from ≥ 65 (34) to ≥ 30 years old (14).  The average percent of vitamin B12 
deficiency in people over the age of 65 with or without diabetes ranged from 12% up to 64% (6, 
33). Couderc et al conducted a retrospective study in France of older adults in an acute hospital 
setting and found that 57.6% of patients 65 years and older had food-cobalamin malabsorption 
(8). However in 2014 El-Khateeb, a population based study in the country Jordan, found adults 
under the age of 65 had a higher risk of developing deficiency than adults 65 years or older (10). 
In conclusion, the age of vitamin B12 deficiency was variable and further studies would be 
beneficial.    
Medication Use 
Proton pump inhibitors (PPI) are a type of medication used to relieve the symptoms of 
heartburn and acid reflux. The purpose of PPI’s is to decrease the acidity of the stomach, 
preventing acidic stomach contents from flowing into the esophagus. Presse et al, a study 




two percent of the patients were taking some kind of antacid while 41.3% of discharges were 
vitamin B12 deficient (35). The study concluded that the use of PPI’s increased the risk of 
developing vitamin B12 deficiency.  
Vegetarians  
Meats have one of the highest concentrations of vitamin B12 in relation to food sources 
(1). As a result, vegetarians and vegans are both groups with a high risk of vitamin B12 
deficiency (5). Kumar found that vegans had a higher rate of vitamin B12 deficiency that was 
statistically significant compared to non-vegans. Their data were not dependent on the use of 
metformin (21).  
 
Neuropathy related to vitamin B12 deficiency 
 Peripheral neuropathy is a well known symptom of vitamin B12 deficiency (5, 9, 12, 36). 
A retrospective study of patients with vitamin B12 deficiency from a primary care practice found 
that 62% of their patients with diabetes had a form of neuropathy (9). A long term cross sectional 
study also found that 75% of patients with diabetes taking metformin had neuropathy, while 
46.5% of those not taking metformin had a form of neuropathy (5). The authors concluded that 
metformin had a significant negative correlation on risk of neuropathy (16). Another cross-
sectional longitudinal study concluded that 60% of those with insulin-dependent diabetes had a 
form of neuropathy and 59% of non-insulin dependent patients had neuropathy. Symptoms of 
neuropathy only occurred in 20% of all of their participants with neuropathy (36). Overall 60-
70% of individuals with diabetes, not dependent on medication or insulin use, will have a risk of 






 The signs and symptoms of vitamin B12 deficiency can take up to 6 years to be detected 
in the blood (33). Long-term studies looked at the time it takes to become vitamin B12 deficient. 
Kumar found that metformin caused an increase in vitamin B12 deficiency after 1 year of 
exposure (5). Similarly, Pflipsen et al concluded that the longer a patient had been diagnosed 
with diabetes and taking metformin the greater risk they had of being vitamin B12 deficient (4). 
The same was found for dosage of metformin taken (21).  Jager et al found that vitamin B12 
deficiency is not a temporary issue, but is a progressive problem that will increase with time 
(14). In contrast, Bauman et al found a decrease in serum B12 three months after the initiation of 
metformin treatment (13).   
 
Obesity and Vitamin B12 deficiency:  
Only two studies related vitamin B12 deficiency to obesity (10, 16). A population-based 
study found that 30.5% of normal and overweight older adults were vitamin B12 deficient, while 
34.4% of obese older adults were vitamin B12 deficient. A prospective descriptive study showed 
obese children had an average of 130 pg/mL lower serum B12 levels when compared to normal 
weight children. Ten percent of obese children had low serum B12 levels, while 2.2% of normal 
weight children had low levels (16). Neither study looked at obesity as an independent variable 
for vitamin B12 deficiency.  
The rational for why obesity may increase the risk of vitamin B12 deficiency is unclear, 
but may be related to the use of heartburn medications. Heartburn, or acid reflux, is a common 
byproduct in adults who are overweight and obese. Many medications taken to relieve heartburn 




2 diabetes are overweight or obese (CDC, WHO) and 24% of individuals with Type 2 diabetes 
experience heartburn (37). NHANES has found that 18.1-27.8% of the US population regularly 
use Proton Pump Inhibitors for heartburn (38). High blood sugars can also relax the lower 
esophageal sphincter along with slowing down esophageal peristalsis (39).  The relaxation of the 
LES sphincter can then lead to heartburn and thus increase the usage of medications. 
 
Interventions to prevent vitamin B12 deficiency:  
Vitamin B12 supplementation  
Vitamin B12 supplementation includes oral cyanocobalamin, intramuscular 
cyanocobalamin, and oral methylcobalamin (8, 9, 15, 40). Tucker et al conducted a prospective 
cohort study with the offspring of the Framingham Cohort study. The participants were from a 
healthy population, 26 years of age or older. The study looked at oral and intramuscular vitamin 
B12 supplements (17). The oral supplements ranged from 1000µg/day to 1000µg/month of 
cyanocobalamin. The intramuscular dose varied from 1000µg/day for 1 week to 1000µg/month. 
The study found that individuals who took any form of vitamin B12 had an 8% risk of 
developing vitamin B12 deficiency while non-supplement users had a 20% risk of developing 
deficiency. Although oral and intramuscular treatments both found significant improvement in 
serum B12 levels, the study suggests using intramuscular therapy if serum B12 is <149pg/mL for 
the quickest results (17).  NHANES found no association between a vitamin B12 deficiency risk 
and vitamin B12 supplementation in people over the age of 50 taking metformin. People taking 
up to 6µg of vitamin B12 had a 14.1% risk of becoming vitamin B12 deficient, while people 
taking >6µg had a 1.8% risk of developing deficiency (15).. Finally, a systematic review on 




any form of vitamin B12 supplementation would most likely not improve neuropathy measures 
or symptoms of the disease (40).  In conclusion, the limited studies to date did not find 
conclusive evidence that supplementation of either calcium or vitamin B12 would decrease 
subjects’ risk of developing vitamin B12 deficiency.  
Fortified food vitamin B12 supplementation  
 Increasing foods high in vitamin B12, along with using fortified foods to prevent vitamin 
B12 deficiency has been studied.  The Frammingham Offspring study looked at fortified foods 
such as breakfast cereals and (17). The study found that individuals who consumed fortified 
cereal 4 times a week or more, had a 14% risk of becoming deficient while non-fortified users 
were 23% more likely to become deficient. The study also concluded that fortified foods such as 
cereal might be better absorbed than meats and other protein sources (17).   
Calcium supplementation  
Because calcium is needed for vitamin B12 absorption, interventions have tested calcium 
and vitamin B12 supplementation, through oral supplements and fortified foods, to reverse or 
prevent a vitamin B12 deficiency (8, 9, 13, 15, 17, 35, 40, 41). A randomized control trial of 
patients consuming metformin studied the use of calcium carbonate to reverse vitamin B12 
deficiency (13).  A calcium carbonate (1.2g/day) pill was given to participants daily after 3 
months of metformin therapy. The results showed that calcium carbonate helped increase serum 
transcobalamin II holoTCII levels but did not significantly increase serum B12 levels. Presse et 
al conducted a cross sectional study on calcium supplementation of patients consuming PPIs 
(35). The cross sectional study collected medical charts from a Geriatric Hospital, where the 
calcium supplements were varied forms of calcium carbonate ranging from 250-1,500mg/day 




risk for being vitamin B12 deficient. The study concluded that calcium supplements, along with 
the use of PPIs was a strong effect modifier in the prevention of vitamin B12 deficiency. Overall, 
the use of calcium supplementation in preventing vitamin B12 deficiency was inconclusive and 
more research needs to be collected.  
 
Conclusion  
Vitamin B12 deficiency is caused by medication use, age, diet and malabsorption (4, 5, 
14) . The consequences of vitamin B12 deficiency include diabetic neuropathy (14), memory 
loss (19) and cardiovascular disease (2) . The use of the drug metformin increases the risk of 
vitamin B12 deficiency by 7% (14) and almost 60% of patients with vitamin B12 deficiency 
have a form of diabetic neuropathy (36). While causes of vitamin B12 deficiency have been 
researched, minimal studies have looked at the long term effects of metformin and obesity as a 
factor of deficiency. The use of vitamin B12 and calcium supplementation is still controversial, 
and there is not enough evidence to prove its effectiveness. Recent studies also suggest vitamin 
B12 deficiency is increasing in younger adults and even adolescents. More exploration is needed 













Chapter 3: Methods 
Larger Study 
Overview 
 The data were collected from the Activity for Diabetic Polyneuropathy: ADAPT study, a 
randomized clinical trial ROI: 5R01DK064814-10. The study was developed by investigators 
from the Physical Therapy Departments at the University of Utah Medical Center and the 
University of Kansas Medical Center (KUMC) with collaboration from the Department of 
Dietetics and Nutrition. The principal investigators are Dr. John Robinson Singleton of Utah and 
Dr. Patricia Kluding of KUMC.  The primary aim of the ADAPT study is to determine if an 
integrated program of moderate supervised exercise and actigraphy, based on anti-sedentariness 
counseling, is an effective therapy for DPN. The second objective is to better evaluate the 
clinical meaning of change in intraepidermal nerve fiber density and to determine the 
intervention’s impact on epidermal regeneration and inflammation.  
Sample 
 Participants for the ADAPT study are recruited from patients with T2DM seen in the KU 
Hospital, University of Utah Hospital and community clinics and with additional recruitment 
efforts at affiliated clinics that conduct screenings for diabetic retinopathy. Participants are also 
recruited directly from the KUMC Neuromuscular clinics and Veterans Administration Centers 
as appropriate. Provider letters and clinic fliers are utilized to enhance enrollment. Inclusion 
criteria includes men or women between 30-70 years of age with T2DM defined by American 
Diabetes Association (ADA) criteria (42). They must have peripheral neuropathy, based on the 
Toronto Diabetic Neuropathy Expert group criteria (43), and be under the care of an identified 




neuropathy. Individuals with obesity, hypertension, diabetes or hyperlipidemia considered in a 
dangerous range (Body Mass Index (BMI) >45, HgbA1c >10, systolic BP >170, or diastolic BP 
>110, and those with triglycerides > 750 mg/dL) are also excluded.  
Other enrollment criteria include vitamin B12, thyroid stimulating hormone, antinuclear 
antibody, serum protein electrophoresis and immunoflixation laboratory values all normal within 
the last 12 months. A final exclusion criteria for the ADAPT study is having low serum B12 
levels; therefore, participants in this study are not vitamin B12 deficient. Individuals with serum 
B12 levels <200ng/L at screening are required to supplement with 1-2 mg of oral vitamin B12 
for three months before recheck. Individuals with serum B12 levels of 200-299 ng/L are required 
to test their methymalonic acid blood levels. If they are elevated, then oral vitamin B12 
supplementation is required for three months prior to rescreening. Individuals with serum B12 
levels >300 ng/L are accepted into the study. 
Setting 
 The study is conducted through the University of Kansas Medical Center and the 
University of Utah Medical Center. Recruitment will occur for 42 months and each participant 
will be enrolled for 18 months. 
Ethics 
 The Human Subjects Committee at both KUMC and Utah approved this proposal. 
Written informed consent is obtained. Participants are compensated $50 for completing each of 
the following visits: Baseline 1, Baseline 2, Month 3, Month 9 and Month 18, for up to a 







(Informed consent, medical history, 
neuromuscular physical examination) 
Baseline 1
(Distal leg biopsy, labs)
Baseline 2




Assessment: 12 weeks, 9 months, 18 
months 
Intervention
Physical Activity: twice weekly
Meet with Registered Dietitian: semiweekly 




Larger ADAPT Study Methods 
Screening and Baseline 1 
 During the screening process, after written informed consent is obtained, the investigator 
takes a medical, family and neurological history via forms created by the University of Utah. A 
vitals assessment of pulse, heart rate and blood pressure, and a focused, standardized 
neuromuscular physical examination, which incorporates the Utah Early Neuropathy Scale 
(UENS), a standardized neuropathy exam scale (44) is administered. Once individuals are 
approved, they participate in the Baseline 1 visit. During Baseline 1, the following procedures 
are performed to assure they meet the entry criteria and have the qualifications of “Peripheral 
Neuropathy,” measured by a distal leg skin biopsy, physician supervised graded maximal 
exercise test and laboratory tests which include HbgA1c, fasting lipid panel, serum vitamin B12, 
thyroid stimulating hormone and antinuclear antibody labs.  
Demographics and Medication use  
Age and medication usage is collected from the participants by self-report on Utah survey 
forms along with their medical chart provided by their Primary Care Provider. 
Serum Vitamin B12 
The blood was drawn by a nurse at the Clinical and Translational Science Unit, processed 
and shipped to The University of Utah for analyses. Serum B12 was measured in mg/dL. The 







Participants had their height, weight and waist circumference measured by the blinded 
Baseline 1 assessment team. Weight was measured in kilograms using a digital weight scale.  
Participants wear their normal clothes and the removal of shoes is voluntary.  The team notes, on 
the assessment form, whether or not shoes are removed. The weight appears on the screen and 
the measurement is recorded on the assessment form. For assessment of height, participants are 
asked to stand up straight against the stadiometer backboard with their body weight evenly 
distributed and both feet flat on the platform. They are instructed to stand with their heels 
together and toes apart. The team checks to ensure the back of the head, shoulder blades, 
buttocks, and heels make contact with the backboard. The stadiometer headpiece is lowered so it 
rests firmly on top of the participants’ heads with sufficient pressure to compress their hair. 
Participants are instructed to stand as tall as possible, take a deep breath and hold the position. A 
single measurement is taken, and the team records the height along with whether the subject is 
wearing shoes.  
Waist circumference is measured by having participants stand with feet shoulder width 
apart and arms crossed over their chests. The hips are palpated to locate the top of the iliac crest 
and a line is drawn at this spot between their back and abdomen. The measuring tape is placed 
horizontally around the participants’ abdomens. A spring hand measuring tape is used to control 
pressure exerted on their abdomen. The participants are instructed to relax and take 3 normal 
breaths. The measure is taken from the zero line of the tape at the end of a normal expiration. 
Waist circumference is only measured once.  
BMI is calculated from height and weight: bodyweight in kilograms divided by height in 




25.0-29.9 kg/𝑚2as overweight, and 30.0- 45kg/𝑚2 as obese. All anthropometric data are added 
to the participants’ personal binder and RedCap database. 
Baseline 2 
Once participants pass Baseline 1 requirements, they complete the Baseline 2 visit. In 
preparation for the Baseline 2 evaluation, participants are asked to complete a standard 3-day 
food record over a period spanning two weekdays and one weekend. During the visit, 
participants discuss their completed three-day food record with a registered dietitian, review 
weight and metabolic lab results, and receive uniform basic nutritional counseling from the 
registered dietitian. The standardized 20-minute session provides information based on the 
Diabetes Prevention Program goals: reduce total calories and fat calories to achieve weight loss.  
Dietary Intake  
A 3-day food record document was created by the University of Utah and can be found in 
the appendix. The record consists of directions and examples on how to complete a 3-day food 
record. The University of Utah’s registered dietitians created the record and trained the KUMC 
registered dietitian via email on how to collect the record. The KUMC registered dietitian 
provided training to the Baseline 1 assessment team on how to explain the diet record to the 
participants at the Baseline 1 visit. Participants are required to fill out all food and beverages 
consumed over a consecutive 3 day period of two weekdays and one weekend. They are 
instructed to include time of day, location, and as many details of the meal consumed, including 
preparation and any additional ingredients added to the meal.  
Participants meet with the registered dietitian for the first time during the Baseline 2 visit. 




sure all food and beverages consumed are included and obtains clarifications as needed. The 
registered dietitian then asks for any additional dietary, herbal or other supplements taken and 
adds it to the supplement section on the record. Once the record is complete, the registered 
dietitian enters the food records into the Food Processor 10.15.0 database structure version 9.8.2. 
Randomization 
 Once both baseline visits are completed, participants are randomized into two groups: the 
intervention group, which receives personalized dietary counseling every other week for the first 
12 weeks and monthly thereafter, and the control group which receives no additional counseling. 
The intervention group meets twice weekly for the first 12 weeks. Goals include aerobic exercise 
of 70% VO2 reserve for 50 minutes; 3 sets of 15 repetitions of 3 upper and 3 lower body strength 
exercises at 60-70% of repetition maximum twice a week. Participants are then given standard 
counseling by a registered dietitian on diet (target of 7% weight reduction) every other week for 
the first 12 weeks. Weight and waist circumference are obtained at each visit and charted as a 











Present Study Methods  
Subjects 
Participants in the present study included 16 men and 14 women. Fifteen of the 
participants were from Utah and fifteen were from KUMC. 
Materials 
 Three-day diet records, body weight, anthropometrics measures, serum vitamin B12 
values and statistical analysis software were needed to complete the study. For this purpose of 
the present study, the 3-day diet records were entered into a nutrient analysis software program, 
Nutrition Data System for Research (NDSR) software version 2016, developed by the Nutrition 
Coordinating Center (NCC), University of Minnesota, Minneapolis, MN. The records were 
entered into NDSR for the purpose of the present study because the database does not allow 
missing values for nutrients while other databases allow missing values.  
Analysis of Data 
The anthropometric data along with medications were pulled from a RedCap database 
where it had been entered by the KUMC and Utah assessment teams. Results from the 3-day 
food records were pulled from NDSR. Baseline demographics and outcome variables were 
summarized using descriptive statistics. A one-way analysis of variance (ANOVA was used to 
compare individuals taking metformin and non-users). A regression analysis was used to 
determine the relationship between serum B12 and the following variables: dietary vitamin B12 
(food and beverages), BMI, age and vitamin B12 supplement usage.   
The baseline 3-day food records were entered in NDSR by a registered dietitian trained in 




registered dietitian for quality assurance prior to analyzing data. The NDSR Foods 2016 
Database Documentation file and output files 01, 04 and 12 were used for the analyses.   
To determine the average daily intake (µg) of vitamin B12 in adults with diabetic 
peripheral neuropathy, the average of all dietary sources of vitamin B12 was calculated using the 
Intake Properties Totals file (04) and the average of all supplement sources of vitamin B12 was 
calculated using the DSAM Total 24-hour Supplement Intake file (12) for each participant.  The 
average daily intake vitamin B12 from dietary and supplement sources were then combined for a 
total oral vitamin B12 intake. To assess dietary sources of vitamin B12, the 
Component/Ingredient file (01) was sorted to categorize each food and beverage into 3 source 
types:  animal, fortified food and beverage, or miscellaneous sources. The Foods 2016 Database 
Documentation file was used to assist in identifying specific foods and beverages for each 
category by utilizing the NDSR food descriptions and Food IDs columns. The average daily 
intake of vitamin B12 was calculated for each category by participant and by group. Daily total 
macronutrient distribution and total calories consumed for each participate were totaled and 
averaged. A t-statistic was used to evaluate variances between metformin and non-metformin 











Chapter 4:  Results 
 The purpose of the present study was to determine the average daily intake of vitamin 
B12 in adults with diabetic peripheral neuropathy and whether there was a difference in serum 
vitamin B12 concentrations between those taking the medication metformin vs. non-users. In 
addition, the study aimed to answer whether there was a relationship between vitamin B12 
consumption and serum B12 levels; Body Mass Index and serum B12; and age and serum B12 
levels.  
 Thirty participants, fifteen from Utah and fifteen from KUMC each had a 3-day food 
record along with baseline demographics, medication and supplement usage. The mean age of 
the sample was 59.8 ± 7.03 years with ages ranging from 38 to 70 years old. The study consisted 
of 16 men and 14 women. The mean Body Mass Index was 33.45 ± 6.32 kg/m2 (range 21.5 to 
51.4). Twenty-three (77%) of the subjects had a BMI greater than 30 kg/m2, categorizing them as 
obese. The average serum B12 level was 650.67 pmol/L  ± 413.58 pmol/L with levels ranging 
from 222 pmol/L to >2000 pmol/L. Table 1 depicts the characteristics of the participants.  
 Seventy percent (21/30) of participants were on the drug metformin and 37% were taking 
a vitamin B12 supplement. There was no difference between metformin users and non-users in 








 Table 1: Demographics and Differences between Metformin Users vs. Non-Users  
 
 
 The average energy intake from the 3 day food records was 1,728 kcal per day. 
Macronutrient distribution ranges were 42% of the energy from carbohydrate, 37% from fat and 
17% from protein. The mean dietary vitamin B12 intake was 4.3 µg. Forty three percent (43%) 
of total dietary vitamin B12 came from animal sources, while 20% was derived from fortified 
foods. One subject was a vegetarian and only 48% of the participants consumed foods fortified 
with vitamin B12. Metformin users had a significantly lower percent of energy from protein 
versus non-users (16.1% vs. 19.6%, respectively). No other significant differences were observed 













Age (years) 59.8 ± 7.0 59.6 ± 4.2 59.9 ± 8.0 0.88 
BMI (kg/m2) 33.5 ± 6.3 34.28 ± 6.2 33.1 ± 6.5 0.64 
Serum Vitamin B12 
(pg/mL) 
650.7 ± 413.6 806.1 ± 492.7 584.0 ± 367.9 0.24 
Vitamin B12 Supplement 
dose (µg/d) 
92.1 ± 455.1 8.6 ± 16.3 127.9 ± 543.8 0.32 





  Medication Use 








Energy (kcal) 1728.3 ± 504.8 1547.2 ± 324.5 1805.8 ± 553.4 0.12 
Fat (g) 73.6 ± 22.9 69.2 ± 13.9 75.5 ± 25.9 0.39 
Carbohydrate (g) 188.1 ± 61.9 163.9 ± 57.4 198.5 ± 71.9 0.16 
Protein (g) 72.3 ± 22.9 73.3 ± 24.5 71.8 ± 4.17 0.88 
Percent Fat (%) 37.3 38.8 37.2 0.53 
Percent Carbohydrate (%) 43.1 41.2 43.8 0.43 
Percent Protein (%) 17.1 19.6 16.1 0.04 
Total Vitamin B12 (µg) 4.3 ± 2.6 4.6 ± 2.2 4.2 ± 2.8 0.67 
Vitamin B12 from Animal 
Sources (µg) 
3.4 ± 1.9 3.9 ± 1.5 3.1 ± 2.0 0.27 
Vitamin B12 from 
Fortified Foods (µg) 
0.91 ± 1.5 1.4 ± 2.3 0.69 ± 1.0 0.39 
Vitamin B12 for Misc. 
(µg) 
0.07 ± 0.10 0.05 ± 0.07  0.08 ± 0.1 0.42 
Vitamin B12 from 
Supplements (µg) 
92.0 ± 455.1 4.8 ± 6.7 127.8 ± 543.8 0.32 
Total Vitamin B12 from 
Diet and Supplements 
(µg) 
94.9 ± 455.1 10.2  ± 10.6 131.2 ± 547.0 0.32 
 
There was no significant difference in serum B12 levels between metformin users and 
non-users (p= 0.182). There was also no relationship between total dietary intake of vitamin B12 




and serum vitamin B12 concentration (p= 0.17). However, there was a significant relationship 
between vitamin B12 supplement use and serum vitamin B12 (p=0.031). There were also no 
significant relationships between serum vitamin B12 and the demographics of age, BMI, or 
obesity status. Table 3 shows the results from the regression analysis.  
 
Table 3: Regression Analysis for Independent Variables 
 
 
A pairwise correlation matrix was used to look at the relationship of each independent 
variable. Table 4 shows the statistical significance of supplement use with serum B12. The table 
also illustrates the correlation of fortified foods and animal sources to overall vitamin B12 
consumption. Fortified foods (p= 0.00) had a stronger correlation to overall vitamin B12 intake 




  Serum B12 pg/mL   
Variable S SE B Β p-value 
Dietary B12 (µg) -41.2 29.3 -0.25 .170 
BMI (kg/m²) -1.3 12.4 -0.2 .9150 
Age (years) 10.7 10.9 .181 .338 









Chapter 5:  Discussion 
Overall Daily vitamin B12 intake 
 The average daily dietary intake (µg) of vitamin B12 in the present study was 4.3 µg per 
day.  The Estimated Average Requirements (EAR) for men and women age 30-70 years of age is 
2.0 µg per day. Data collected from the 3-day food records revealed five individuals did not meet 
the EAR for vitamin B12 which indicates a high probability that their diets are inadequate in 
vitamin B12. These results differ significantly from the Frammingham offspring study that found 
average dietary B12 consumption in adults 26-83 years of age was 8.7 ± 0.3 µg per day (17).  
The Frammingham offspring population reported by Tucker et al did not have diabetes and 
dietary intake was collected using a semi quantitative 126 question food frequency questionnaire 
and calculated total vitamin B12 intake including supplements, fortified foods and animal 
sources. The present study collected dietary intake via a 3-day food record and supplement 
intake. The type of food record utilized, sample population characteristics and inclusion of 
supplements could explain differences in results. Tucker et al did not publish average energy 
consumption for comparison which could also be a confounding variable. Few vitamin B12 
studies have collected food records from participants, therefore our study could show a more 
accurate description of average vitamin B12 intake.  Regardless, the results call for further 
research to explore the validity and mechanism behind the varying results.  
Metformin  
De Jager et al and Kumar et al found that taking metformin significantly lowered serum 
vitamin B12 in patients with diabetic neuropathy more than those not taking metformin by 19% 





participants with T2DM consuming and not consuming metformin(5) He found that mean serum 
B12 was lower in the group taking metformin (410mg/dL ± 230.7 vs 549.2 ± 244.7mg/dL). De 
Jager et al conducted a randomized placebo control trial that found participants with T2DM who 
started on metformin developed a fall in serum B12 levels by an average of 89.8pmol/L (14). 
The study also looked at risk of vitamin B12 deficiency with the use of metformin. Analysis of 
participant data in the present study did not control for dosage of metformin or length of use. 
Despite the similarities in the studies, the present study did not find the same association as de 
Jager and Kumar. The difference between the previous studies and the present study cannot be 
determined from these data. However, it can be speculated that it may be due to the duration of 
metformin use and sample size. For example, NHANES 1999-2002 separated metformin use by 
years (15). Participants that had taken metformin >10 years had the highest prevalence of serum 
B12 deficiency. A further explanation may be the fact that individuals with low serum vitamin 
B12 were excluded from participation in the present study.  
Vitamin B12 consumption  
 The present study supports the findings from other studies that taking a vitamin B12 
supplement has a positive relationship with serum B12 (10, 15, 17). El-Khateeb found taking a 
B-Complex supplement protected against vitamin B12 deficiency in individuals with T2DM 
(10). Tucker et al from the Frammingham Offspring study found that any supplement containing 
vitamin B12 protected against deficiency, while NHANES data indicated that vitamin B12 
supplementation decreased prevalence of deficiency(15). The present study strengthens the 
recommendation for individuals with diabetes to consume a vitamin B12 supplement to protect 





Body Mass Index 
 The present study did not find a positive relationship between BMI or obesity status and 
serum vitamin B12 levels. This contradicts data from the NHANES 1999-2006 survey in which  
a positive relationship was reported between serum B12 levels and a BMI of 25-30kg/m2 (15). 
Similarly El-Khateeb et al in their population based study found obese individuals (≥ 40 kg/m2) 
to have the highest rates of serum vitamin B12 deficiency (10).  The NHANES sample size was 
8,488 participants and El-Khateeb collected data on 5,640 individuals. The differences could be 
explained by the small sample size of only 30 participants as well as the exclusion criteria of 
individuals with a serum vitamin B12 <300pmol/L. Further, NHANES data revealed significant 
relationships in overweight individuals while El-Khateeb found significant relationships only in 
obese individuals. The two studies do not share a consensus on weight in relation to vitamin B12 
and both studies could have confounding variables, such as PPI use. Finally, the present study 
has 73% of the subjects distributed into the obese category. El-Kahteeb included individuals with 
a BMI >40 kg/m2 while this group was excluded in the present study. A more evenly distributed 
sample size might have affected the results.    
Age 
 Solomon et al, Couderc et al and Reinstatler et al found that the prevalence of vitamin 
B12 deficiency increases with age (8, 15, 41). This is partially due to a decrease in intrinsic 
factor production and food-cobalamin malabsorption (8). Our study did not find a relationship 
between age and serum vitamin B12 levels.  
 El-Khateeb et al found in his population based study that individuals between the ages of 





any individuals under the age of 38, but the data could strengthen El-Khateeb’s study in showing 
that age is not a factor for vitamin B12 deficiency. The present study, as well as data from El-
Khateeb’s study, could represent new findings in age and its relationship to serum B12 levels.  
More research studying the relationship between age and serum B12 levels is needed. 
Nevertheless, based on recent data, testing for deficiency starting at a younger age would be 
recommended.    
Supplementation 
 The present study found that supplements containing vitamin B12 have a positive 
relationship with serum vitamin B12 levels. This compares to the NHANES 1999-2000 survey 
that found, independent of vitamin B12 dosage, taking a supplement will decrease your risk of 
vitamin B12 deficiency (15). Similarly Pflipsen et al states that a multivitamin protects 
individuals with diabetes from vitamin B12 deficiency (4). Only 37% of the individuals in the 
present study were taking a supplement containing vitamin B12. The Institute of Medicine 
suggests individuals over the age of 50 should consume either vitamin B12 fortified foods or a 
supplement containing vitamin B12 to meet their RDA(29). The present study supports previous 
research that supplementation protects against low serum B12 levels. 
 Limitations 
 There are several limitations to the present study. It is a secondary analysis using 
previously collected data. Therefore, the information available is limited and there is no 
opportunity for further clarification of dietary records, weights, etc. In addition, the dietary 





participants at Baseline 1. Their use of supplements could be inconsistent and could provide false 
information on vitamin B12 supplement usage. 
  Human error can occur during data entry into NDSR, the software program used for 3-
day food records. However, we tried to limit coding errors by having all the data entry verified 
by a second qualified diet entry coder. The study is split between two universities, with separate 
teams collecting data including anthropometric measurements. Discrepancies of data collection 
could have occurred among the two universities.  
The study demographics are not evenly distributed.  Twenty-three out of thirty (77%) of 
the individuals were in the obese category, while twenty-one out of thirty (70%) of the 
individuals took metformin. The amount of overweight and obese subjects could have affected 
the analysis of BMI to serum vitamin B12 along with metformin use to serum vitamin B12.  
The sample size was small and statistical significance may be weak compared to a study 
with a larger sample size. Finally, a major exclusion criterion was having a serum B12 level 











Chapter 6: Summary 
 Previous studies have had conflicting results regarding age, BMI, medication use and 
supplements on their impact on serum B12 levels (5, 14, 17). Furthermore, few studies have 
looked specifically at individuals with diabetic peripheral neuropathy and their serum B12 levels. 
No studies reviewed have used 3-day food records to analyze total nutrient intake, macronutrient 
and micronutrient distribution. Many studies focus on medication and demographics vs. 
supplementation (4, 14, 15). The most recent study, El-Khateeb et al (2014), concluded that there 
was not a relationship between old age and serum B12 (10). They also stated that there is a 
positive relationship between BMI and serum B12 (10). Although the present study did not find a 
relationship between BMI and serum B12, it did concur with El-Khateeb’s finding that old age 
did not increase the risk of vitamin B12 deficiency. Thus, the present study strengthens El-
Khateeb’s more recent findings.  
 The present study will hopefully fill the gaps of previous research by specifically looking 
at dietary and supplement B12 consumption and serum B12 levels. More research is needed for 
the specific analysis and relationship of animal sources vs fortified food sources on serum B12 
levels. The present study can strengthen new research on serum B12 deficiency and the 
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